Current Clinical Trials


Current Cardiology Clinical Trials

Interested in participating in Clinical Trials?

Please contact CTSRDS@augusta.edu or call 706-721-0193

ARTEMIS

  • Artemis: Principal Investigator, Dr. Arora:  Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction
  • Registry study for STEMI or NSTEMI patients. Pays co-pays for anti-platelet therapy to determine the effect on compliance.
  • Must have private or government insurance of some type that provides medication coverage

AUGUSTUS CV185316

Augustus: Principal Investigator, Dr. Sharma: An Open-Label, 2x2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs Aspirin placebo in patient with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention
         Apixaban - Aspirin vs Placebo               VKA – Aspirin vs. Placebo  

GENETIC AF

  • Genetic-AF: Principal Investigator, Dr. Berman:  A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol XL for Prevention of Symptomatic Atrial Fibrillation/Atrial flutter in Patients with Heart Failure
  • For patients with β₁389 Arg/Arg Genotype.

Compares superiority on time to first recurrence of AF/AFL, EF < 50%, Hx CHF, No more than 2 DCCV within last 12 months

Magnetic VT

Magnetic VT:  Principal Investigator, Dr. Berman: A prospective, multi-center, post market, randomized controlled trial comparing VT ablation outcomes using remote MAGNETIC navigation guided substrate mapping and ablation versus manual approach in low LVEF population

TEVA/Dream-HF

TEVA/Dream-HF: Principal Investigator, Dr. Weintraub: A Double-Blind, Randomized, Sham-procedure-controlled, Parallel Group efficacy and safety of Allogeneic Mesenchymal Precursor Cells (CEP-41750) in patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Non-ischemic Etiology.  Dx HF x 6 months, EF < 40%, NYHA Class II or III

Stable med dosages x 1 month (diuretic titration allowed) I month since hospitalization, MI, IV therapy (milrinone) 2 months since PCI/CABG

Zero AF

  • Zero AF: Principal Investigator, Dr. Sorrentino:  Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation
  • The primary objective of the study is to establish the safety and effectiveness of the Blazer Open-Irrigated ablation catheter for the treatment of drug refractory, recurrent, symptomatic, paroxysmal atrial fibrillation (PAF).

Ixmyelocel: 55-1202-1

  • Ixmyelocel: 55-1202-1: Principal Investigators, Drs. Berman/Weintraub: Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate, Safety and Tolerability of Transendocardial Injection of Ixmyelocel-T in Subjects with Heart Failure due to Ischemic Dilated Cardiomyopathy (IDCM)
  • Study now completed. Published in Lancet 2016:387:2412-21. The primary efficacy endpoint was observed in 47 patients: 50 events in 25 (49%) of 51 patients in the placebo arm and 38 events in 22 (38%) of 58 patients in the Ixmyelocel T group, which represents a 37% reduction in Cardiac Events compared with placebo.  Two subjects who received placebo are being brought in to receive Ixmyelocel-T

 LEARn more about our studies

researchpicture